The present study evaluates patients after interventional therapy of valvular diseases of the right heart. Follow-up examinations include medical history taking, laboratory measurements and an echo. The aim is to assess the different interventional therapies and their impact on patient's outcome.
The subject of the study is to register interventional therapies of right heart diseases (such as "cardioband" and "edge-to-edge" techniques of the tricuspid valve) performed in Berlin/ Brandenburg (primarily at the Charité, Universitätsmedizin Berlin). Based on the development and the increasing use of interventional therapies in tricuspid and pulmonary valve diseases, the impact on the patients' symptoms and life expectancy after interventions will be investigated. The aim is to identify patient subgroups that benefit the most. Primary endpoints: Total mortality, cardiovascular mortality, heart failure hospitalization. Secondary endpoints: NYHA class, NTproBNP, liver and kidney function (laboratory measurements), valve function, cardiac function, and cardiac morphology.
Study Type
OBSERVATIONAL
Enrollment
200
Catheter-based therapy of valve diseases of the right heart with various devices (e. g. TriClip, Cardioband).
Charité - Universitätsmedizin Berlin
Berlin, Germany
RECRUITINGOverall mortality
Number of deceased participants after 2 months after intervention
Time frame: 2 months after intervention
Cardiovascular mortality
Number of deceased participants after 2 months after intervention (cardiovascular cause of mortality)
Time frame: 2 months after intervention
Unscheduled hospitalization for heart failure progression
Number of participants with unscheduled hospitalization for heart failure progression after 2 months after intervention
Time frame: 2 months after intervention
NYHA class
New York Heart Association (NYHA) class (to rate dyspnea in heart failure patients)
Time frame: 2 months after intervention
NTproBNP
Laboratory measurement of NTproBNP 2 months after intervention
Time frame: 2 months after intervention
valve function
Echocardiographic quantification of valve function (proximal isovelocity surface area \[PISA\] method, effective regurgitant orifice \[ERO\], vena contracta \[VC\]) after 2 months after intervention
Time frame: 2 months after intervention
liver function
Laboratory measurement of bilirubin 2 months after intervention
Time frame: 2 months after intervention
kidney function
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Laboratory measurement of creatinine 2 months after intervention
Time frame: 2 months after intervention
cardiac function
Echocardiographic measurement of cardiac function (left ventricular ejection fraction, tricuspid anular plane systolic excursion) after 2 months after intervention
Time frame: 2 months after intervention
cardiac morphology
Echocardiographic measurement of cardiac morphology (right ventricular and right atrial diameter) after 2 months after intervention
Time frame: 2 months after intervention